Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy.
Saved in:
| Title: | Immunogenicity assessment for vidutolimod: a risk-driven approach for a simplified 1-tiered, singlicate anti-drug antibody testing strategy. |
|---|---|
| Authors: | Valentine JL; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Shank S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Fred Lucena LM; Immunologix Laboratories, Tampa, FL, United States., Wang Z; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Stern CM; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Kim BC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Lu K; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Prabhu S; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States., Partridge MA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2026 May 19; Vol. 17, pp. 1751717. Date of Electronic Publication: 2026 May 19 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1751717 |
